Leveraging Next-Gen Therapies, Advanced Purification, and Strategic Collaborations in Pharma Production

Why It Matters

These trends enable pharma firms to improve profitability on high‑value biologics, accelerate time‑to‑market, and maintain competitive advantage in a rapidly evolving therapeutic landscape.

Summary

In a 2026 industry outlook interview, Laine Mello, director of Marketing at Ecolab Life Sciences, said the pharmaceutical sector is under margin pressure and is shifting toward next‑generation therapies such as biologics and advanced modalities. To support these complex products, Ecolab is promoting high‑capacity chromatography resins that boost yield and recovery in biosimilar and second‑generation molecule manufacturing. The company also highlighted the broader move to digitalization and continuous processing to cut costs while maintaining regulatory quality, and stressed that strategic partnerships and acquisitions are becoming essential for rapid access to new technologies and therapeutic areas.